FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer

HER2-mutant NSCLC typically has a poor prognosis and limited treatment options

Merck receives EU nod for first subcutaneous formulation, promising faster cancer treatment

This is the first and only subcutaneous immune checkpoint inhibitor available in Europe

Innovent Biologics’ experimental weight-loss drug achieves breakthrough in Phase 3 trial

Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration

Meduloc wins FDA green light for new class of bone-fracture fixation system

The cleared system pairs a flexible nitinol implant with a deployable prong-locking mechanism, delivering rotational and length stability

Chiesi inks agreement with AbbVie subsidiary to push next-generation brain-targeting therapies for rare diseases

HRV Pharma and MetroChem forge CDMO alliance to fast-track NCE-1 API development

Both companies will jointly execute development and scale-up of multiple strategic APIs, including late-stage NCE-1 opportunities

Galmed’s Aramchol shows promise in overcoming gastrointestinal cancer drug resistance

Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma

Merus and Halozyme collaborate to advance subcutaneous Petosemtamab development

Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab

WHO issues first global guidelines for managing diabetes in pregnancy

Uncontrolled diabetes in pregnancy dramatically increases the risk of pre-eclampsia, stillbirth, birth injuries, and long-term cardiometabolic diseases

Abbott unveils new diabetes care formula amid rising global diabetes crisis

The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health